Genentech issues advisory on damaged Herceptin vials
There is a risk that damaged vials may lead to a loss in sterility.
Genentech has informed healthcare professionals that an increased number of complaints have been received regarding damaged and broken vials of Herceptin 440 mg and BWFI (bacteriostatic water for injection) diluent. The affected vials are NDC# 50242-0134-68, List # 15534.
There is a risk that damaged vials may lead to a loss in sterility, which can cause infections in patients, according to Genentech. The company, however, believes the risk to patients is negligible because of a low occurrence rate and the obviousness of the affected vials.
Healthcare professionals should inspect cartons of the product for signs of leakage, cracks, and other damage to the vials; observe the vials during reconstitution; and check for loss of vacuum in the containers.
The company said it has not identified any systemic error in the internal manufacturing process for Herceptin that would cause the damage.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.
Psychiatric Pharmacist Working to Optimize Treatment, Improve Patient Safety
December 13th 2024A conversation with Nina Vadiei, PharmD, BCPP, clinical associate professor in the Division of Pharmacotherapy at University of Texas at Austin College of Pharmacy and a clinical pharmacy specialist in psychiatry at the San Antonio State Hospital.
